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Abstract: There are an estimated 11.7 million methamphetamine (MA) abusers in the United States and epidemics of  
MA addiction are occurring worldwide. In our human laboratory and outpatient clinical trials we use innovative methods 
to quantify the severity of MA addiction and test biomarkers that may predict response to therapy or risk of relapse. One 
potential biomarker of addiction is the quantity of abused drug intake. Qualitative urinalysis is used in clinical trials  
and during treatment but provides only a binary outcome measure of abuse. Using non-pharmacologic doses of deuterium 
labeled l-MA we have developed a continuous quantitative measure to estimate the bioavailable amount of MA addicts  
ingest. Brain Derived Neurotrophic Factor is a neurotrophin that encourages growth and differentiation of new neurons 
and synapses. Low BDNF levels are seen in many addictive disorders and BDNF is elevated in recovering MA addicts, 
suggesting BDNF may be a marker of MA addiction. We are investigating the effects of controlled doses of MA on 
BDNF levels and gene regulation and measuring BDNF in our clinical trials. We believe both patients and clinical   
researches will benefit from the addition of new, objective and quantifiable outcome measures that reflect disease severity 
and recovery from addiction. 
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INTRODUCTION 
  Addiction is a chronic disease characterized by harmful 
drug use and relapses after periods of sobriety. Many factors 
are thought to drive relapse, including stress, drug-associated 
cues and allostatic load. But, unfortunately, there are no reli-
able clinical signs or symptoms that predict relapse. This 
situation is not unique to addiction; many diseases lack clear 
cut, easily observable signs of disease progression or im-
provement. In the absence of pathomnemonic signs or symp-
toms of disease activity, analytical tools can be used to as-
sess disease-associated biological parameters. These analytic 
measures are referred to as biomarkers. 
  Biomarker measurements have proven essential in clini-
cal medicine. Many diseases are managed entirely thorough 
analysis of biomarkers. For example, CD4 cell counts and 
HIV viral loads (and not disease-defining criteria like oppor-
tunistic infections) are used to manage HIV. Biomarkers can 
help explain empirical results of clinical trials by relating 
clinical responses to the changes in molecular and cellular 
pathways. In doing so, biomarkers provide an avenue for 
researchers to gain mechanistic insight into differences in 
clinical response that may be influenced by uncontrolled 
variables (for example, drug metabolism) [1]. 
  A biomarker is “a characteristic that is objectively meas-
ured and evaluated as an indicator of normal biological proc-
esses, pathogenic processes, or pharmacologic responses to a 
therapeutic intervention” [1]. We believe it will be   
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impossible to develop addiction pharmacotherapies without 
discovery and validation of biomarkers. 
  In our laboratory, we are testing the utility of two bio-
markers for predicting disease outcome and intensity. To 
help assess the response to therapeutic intervention we are 
using quantitative estimates of illicit MA intake. To assess 
normal and pathogenic biological processes, we are using an 
emerging biomarker of CNS function - Brain Derived Neu-
rotrophic Factor (BDNF). Because our studies are ongoing 
results will not be presented here. In this paper we lay out the 
rationale for these biomarkers and discuss our strategy for 
developing addiction biomarkers. 
  Biomarkers are distinct from clinical and surrogate end-
points. Ideally a biomarker will track with clinical outcomes 
and accurately predict the future. However, many biomarkers 
that are useful in drug development never achieve the ade-
quate predictive power of surrogate endpoints. Biomarkers 
may have the greatest value in early drug development stud-
ies. Biomarkers can be used to establish ‘proof of concept’, 
to separate patients with disease from those without disease, 
as a tool to stage disease, as an indicator of disease prognosis 
and to monitor the response of disease to therapy. Our bio-
marker development program is designed to establish proof 
of concept (BDNF), stage disease (quantitative estimates of 
MA intake), and monitor response to therapy (BDNF and 
quantitative estimates of MA intake). 
QUANTITATIVE ESTIMATES OF ILLICIT METH-
AMPHETAMINE EXPOSURE 
  Pharmacotherapy trials aim to discover medications that 
diminish illicit drug use. The ideal pharmacotherapy would 
produce abstinence without relapse (and be inexpensive and 
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medication interventions will be needed to complement   
one another to achieve a more moderate goal. Short of   
abstinence, a goal would be to decrease drug use, defined  
as a decline in both the frequency and amount of drug use. 
One objective measure of drug abuse is finding the drug   
(or, more commonly, a metabolite) in urine; this has become 
a standard tool. However, as currently used, this is non-
quantitative and yields only a time-series of binary outcomes 
of “positive” or “negative.”  
  The Consensus Statement on Evaluation of Outcome of 
Pharmacotherapy for Substance Abuse/Dependence, states 
that, although it can be very sensitive for detecting drug use 
in usually-abstinent individuals “[toxicology testing] is not 
sensitive in detecting either reductions in drug use or periods 
of up to 2-3 days abstinence in individuals who continue 
some use. The consequence has been that…extremely large 
reductions in use (e.g. perhaps up to 90% reductions in use) 
might be required before even a modest reduction in urinaly-
sis-positive results could be expected.” 
  To address this problem, we have been developing a 
method to estimate the quantity of illicit drug exposure. Our 
method involves administration of small, pharmacologically 
inactive doses of deuterium-labeled l-methamphetamine (l-
MA-d3). l-MA is the non-abused isomer of MA. Prior studies 
in our laboratory indicate that, at the doses we plan to give, l-
MA is pharmacologically inactive [2-4]. 
  In our outpatient trials, subjects will be given daily doses 
of a 5 mg of l-MA-d3 biomarker dose in addition to the ex-
perimental treatment medications. A urine sample is col-
lected at each biweekly visit. The approximate time of inges-
tion of the last illicit dose is obtained using a timeline-
follow-back procedure. Compliance with biomarker dosing 
is assessed by having subjects photograph pills just prior to 
ingestion. Pill photos are sent from cell phone to our server, 
giving a time and date for ingestion of the l-MA-d3 bio-
marker. Thus, data used for quantitatively estimating drug 
exposure are: 
[1] The dose and time of biomarker ingestion; 
[2]  Urine concentrations of deuterium labeed l-MA-d3 and 
non-deuterated MA; 
[3] Time of last abused dose. 
  For renally-excreted drugs with first order elimination 
(like MA), urine concentration is directly related to plasma 
concentration. Although the concentration may vary with 
urine pH, age, creatinine clearance and other factors there 
will always be a constant relationship between plasma and 
urine concentrations. For our method, variability in elimina-
tion of MA does not affect estimation of the abused dose 
because deuterated MA (MAdeut) and non-deuterium labeled 
MA (MAnon-deut) have identical elimination [4-5]. Thus, the 
ratio of MAdeut to MAnon-deut in the urine will be the same as 
the circulating ratios of MA. After distribution, circulatory 
concentrations of MA are directly related to CNS effect site 
concentrations. Thus, urine MAdeut:MAnon-deut  is always a 
function of plasma MAdeut:MAnon-deut and this ratio is directly 
related to concentrations at CNS effect sites. Variability in 
absorption could also affect quantitative dose estimation. 
However, we have shown that l-MA is completely absorbed 
(manuscript under review) and thus, the relative ratio be-
tween the deuterated and non-deuterated moieties reflects the 
relative ratios of MA available to act at CNS effect sites. 
  Our method does not estimate the amount of illicit MA 
used. It estimates the bioavailable amount —the proportion 
that actually has toxic effects— which will be some fraction 
of the amount abused. Thus, the method is robust against 
differences in purity and route of administration of illicit 
MA, eliminating variability in subject estimates of the quan-
tity of drug abused. And our method is robust against differ-
ences in elimination, controlling for intraindividual factors 
such as urine pH and hydration status and interindividual 
variations in metabolism, weight, body fat, gender, and age. 
  Because there is no need to adjust for elimination or 
absorption, it is relatively simple to estimate the illicit 
absorbed effect site dose. We measure urine concentrations 
of MAdeut, ([MAdeut]) and [MAnon-deut] and compare the ratio 
of [MAdeut]:[MAnon-deut]. To arrive at the estimated dose we 
adjust for time of dosing using a T1/2 of 12 hours, deriving a 
semi-quantitative estimated abused dose. The estimate is 
semi-quantitative because: 1) we do not know the true lz (the 
rate constant for T1/2) of MA for each individual subject and 
2) we assume the entire estimated dose was taken at the time 
of last abuse. This assumption simplifies a complex process 
of abuse where variable doses are abused over a hectic time 
course. However, due to the long half-life of MA, assigning 
total intake to the last known abused dose is reasonable, at 
least for a first approximation. There will also be a small but 
constant error in our estimate due to carryover and slow ac-
cumulation to steady state of the l-MA-d3 with daily dosing. 
We are aware of this and will use data from ongoing valida-
tion study to adjust estimates. 
  There are several scenarios where estimates would be 
severely biased or not possible. First, if there is little or no l-
MA-d3 in the urine, it is likely that the subject has not been 
taking either the therapeutic medication or the biomarker. No 
estimate will be made in this case. Second, if subjects abuse 
MA close to specimen collection (within 2 hours) the abused 
dose may not be completely distributed, introducing bias. 
We will also not estimate an abused dose in this case. Read-
ers might suspect that binge abuse would be hard to estimate. 
We have an ongoing laboratory trial to assess the variability 
introduced by a pseudo-binge (five small, hourly MA doses). 
For estimation purposes, we assign the total dose based on 
the time of last reported MA abuse. Readers should also note 
that we expect substantial variation in urine MA concentra-
tions – indeed, the degree of variability has made quantita-
tive estimation of intake seem impossible. However, we do 
not compare absolute levels but the ratio of levels, avoiding 
confounds from prior studies.  
BRAIN DERIVED NEUROTROPHIC FACTOR 
  Brain Derived Neurotrophic Factor (BDNF) is the most 
abundant member of the neurotrophin family of trophic fac-
tors. BDNF encourages growth and differentiation of new 
neurons and synapses. It exerts its effects by binding to tro-
pomyosin receptor kinase B (TrkB) receptor [6]. Antidepres-
sants, acting through BDNF and TrkB, increase hippocampal 102    Current Neuropharmacology, 2011, Vol. 9, No. 1  Mendelson et al. 
neurogenesis, leading to the hypothesis that cellular neuro-
plasticity in the adult brain is necessary for the behavioral 
effects of antidepressants [7]. Thus, BDNF has emerged as 
an alternative to the monoamine hypothesis of depression – 
and, by extension, to addiction [8]. Amazingly, brain-derived 
BDNF can be measured in human serum, suggesting that 
BDNF may be useful as an indicator of potential for neuro-
plasticity. BDNF levels are low in the blood of depressed 
patients [9], those with work stress [10], and the hippocam-
pus of suicide victims [11]. Levels rise during treatment with 
antidepressant [9] or electroconvulsive therapy in treatment 
resistant depression [12]. Low BDNF is associated with ver-
bal memory impairment [13] and with cognitive impairment 
and dementia in women [14], while higher BDNF in the eld-
erly is correlated with better performance on the mini mental 
status examination [15]. 
  BDNF levels have been measured in several groups of 
addicts with the results differing between drug classes and 
drug use status at the time of study. BDNF is low in current 
smokers [16] and rises with smoking cessation [16, 17]. Co-
caine, heroin, and cannabis addicts had low BDNF [18] al-
though see [19]). Low BDNF is reported in alcoholism [20] 
and eating disorders [21, 22]. MA addicts with at least 30 
days of sobriety had increased plasma BDNF [23]. These 
studies show addictive drugs can increase or decrease 
BDNF. However, studying only untreated addicts introduces 
many variables obscuring the specific effects of addictive 
drugs on BDNF. 
  Several animal studies show that BDNF levels and gene 
expression are altered by exposure to amphetamines. In rats, 
BDNF mRNA rises in several regions of the frontal cortex 
after a single exposure to non-neurotoxic dose of MA or co-
caine – and these increases are followed by parallel increases 
in dopamine D3 receptor mRNA expression in the nucleus 
accumbens [24]. In contrast, chronic administration of MA 
or amphetamine (AMP) decreases BDNF levels in the hypo-
thalamus and occipital cortex [25]. Compared to adult rats, 
MA given between postnatal days 11-14 increased BDNF 
above those produced by stress [26] and produced spatial 
learning deficits [27]. In a rodent study on interactions of 
amphetamine and closed brain injury, amphetamine in-
creased brain BDNF [28]. 
  We are studying plasma BDNF as a biomarker in meth-
amphetamine addiction. Because BDNF is expressed by 
lymphocytes, we can track time-dependent changes in BDNF 
expression by PCR analysis [29]. In methamphetamine ad-
dicts with at least 30 days of sobriety, serum BDNF levels 
were increased [23]. This suggests BDNF rises during recov-
ery from methamphetamine addiction. Unfortunately, no 
data are available on BDNF levels in active methampheta-
mine addicts or following controlled methamphetamine ex-
posure. 
  On our studies to assess the use of BDNF as a biomarker 
in MA addiction trials we are determining dose and time 
dependent changes in BDNF after controlled oral doses of 
MA and interactions between BDNF on craving, mood and 
neurocognitive function. Animal and clinical data suggest 
there will be differences between dependent and non-
dependent users. Thus, in our laboratory experiments, we 
study two populations of MA users – relatively light non-
dependent abusers and non-treatment seeking dependent 
abusers – to obtain a fuller understanding of the relationships 
between drug exposure, addiction, mood and BDNF. In our 
outpatient clinical trials we use BDNF levels and gene ex-
pression as outcome variables. This synergistic approach will 
yield a rapid understanding on the relationship (if any) be-
tween BDNF and MA addiction. 
CONCLUSIONS 
  In this paper we have outlined the development of bio-
markers of the amount methamphetamine abuse and recov-
ery from methamphetamine addiction. Clinical trialists will 
clearly benefit from the addition of new, objective and quan-
tifiable outcome measures that reflect disease severity and 
recovery from addiction. Validated biomarkers will also im-
prove clinical decision making and patient care. Basic scien-
tists can help this process by searching for novel markers of 
disease activity followed by active collaboration with clinical 
researchers. 
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